Is this your company? Get featured or correct your listing →
Recent changes
- Oct 15, 2026Oct 15, 2026Iambic Prices $150M IPO At $16, Pops On Nasdaq Debut Pulse story
- Oct 8, 2026Oct 8, 2026Iambic Therapeutics Sets Terms For $150M Nasdaq IPO Pulse story
- Sep 21, 2026Sep 21, 2026Nvidia, Qatar-Backed AI Drug Startup Iambic Files For IPO Pulse story
Latest Pulse
- Oct 15, 2026Iambic Prices $150M IPO At $16, Pops On Nasdaq DebutIambic Therapeutics priced its IPO at $16 a share, raising $150 million and debuting on Nasdaq under IAM, with shares rising 13-16% in Thursday afternoon trading after Pulse covered its upsized terms last week.→
- Oct 13, 2026The IPO Window: Biotech Keeps Pricing, Tech Still WaitsSmall biotech IPOs keep clearing the market while bigger, capital-intensive listings stall: City Therapeutics, TRexBio and Iambic all moved this week while Firmus's $31 billion listing sits withdrawn.→
- Oct 12, 2026City Therapeutics Sets Terms For ~$175M Nasdaq IPOCity Therapeutics set terms for its Nasdaq IPO, offering 9.7 million shares at $17-$19 to raise roughly $175 million, with trading expected to start Friday under the ticker CTY.→
- Oct 8, 2026Iambic Therapeutics Sets Terms For $150M Nasdaq IPOIambic Therapeutics set terms for a $150 million Nasdaq IPO at $15-$17 a share, up sharply from the roughly $100 million it originally sought when it filed in September.→
- Sep 21, 2026Nvidia, Qatar-Backed AI Drug Startup Iambic Files For IPOIambic Therapeutics, an AI-driven drug discovery company backed by Nvidia and Qatar's sovereign wealth fund, filed for a US IPO at a roughly $5.49 billion market cap amid a busy fall pipeline of AI-adjacent biotechs.→